Organogenesis (NSDQ:ORGO) beat The Street on sales for the second quarter of 2019 and boosted its outlook for the rest of the year amid continued strong sales growth in its wound-care business. The Canton, Mass.–based regenerative medicine company reported a loss of $9.65 million, or -11¢ per share, on sales of $64.95 million for the […]
Organogenesis boosts revenue, cuts losses in Q1
Organogenesis (NSDQ:ORGO) posted a smaller loss year-over-year during its first quarter, and boosted its outlook for the rest of the year amid strong sales growth in its wound-care business. The Canton, Mass.–based regenerative medicine company reported a loss of $15.7 million, or 17 cents per share, on sales of $57.1 million for the three months […]
Appeals court reverses Organogenesis win in gender bias, retaliation lawsuit
A U.S. federal appeals court this week reversed a win for Organogenesis in an employment discrimination and retaliation lawsuit from former employees, according to recently released court documents. The U.S Court of Appeals for the Ninth Circuit reversed and remanded the case filed by former employees Angela Gonzales, Linda Boyd and Brandee Colombo against Canton, […]
Shareholders approve Avista, Organogenesis tie up
Private equity firm Avista Healthcare Public Acquisition Corp. yesterday approved its merger with regenerative medicine company Organogenesis. The merger won approval yesterday at separate special meetings of shareholders for both companies, Canton, Mass.-based Organogenesis said. As part of the deal, Avista invested a total of $92 million in the combined company, Organogenesis said. Avista also […]
Avista to acquire Organogenesis
Avista Healthcare Public Acquisition group said last Friday it inked deal to acquire Organogenesis for an undisclosed amount. As part of the deal, Avista Capital Partners private equity firm will invest $92 million into the newly acquired company, which is slated to be listed on the Nasdaq under the ticker symbol “ORGO” following the closing […]
Organogenesis launches new sizing option for PuraPly wound care device
MIT-spinoff Organogenesis announced today that its PuraPly antimicrobial wound care device is now available in a 1.6-cm disc size. The Canton, Mass.-based company’s PuraPly AM product includes a broad-spectrum antibiotic, polyhexamethylene biguanide, embedded into a purified native collagen matrix. The device is cleared to treat an array of wound types, including pressure ulcers, surgical wounds, trauma wounds and […]
RTI Surgical taps director for CFO, fills out roster | Personnel Moves, Sept. 19, 2017
RTI Surgical (NSDQ:RTIX) said yesterday that it’s tapping a board member to be CFO and adding a pair of medical device veterans to its executive roster. Alachua, Fla.-based RTI said it named director Jonathon Singer as its finance & administration chief effective Oct. 2, replacing Robert Jordheim. Singer, who resigned his board seat to accept […]
Organogenesis closes $20m credit facility
Organogenesis said today it closed a $20 million financing facility with Eastward Capital Partners. “Eastward Capital Partners is committed to partnering with technology-forward companies who are leaders in their industry segments. We are excited to partner with Organogenesis to provide the capital to support their growth plans,” Eastward Partner’s Tim O’Loughlin said in a prepared statement. “We […]
Silicon Valley Bank puts up $25m credit line for Organogenesis
Organogenesis said today that it entered into a revolving line of credit agreement with Silicon Valley Bank to provide $25 million in new capital to the regenerative medicine company. “The people of Silicon Valley Bank are not only excellent bankers, but what sets them apart is they also understand business,” Organogenesis chief financial officer Tim […]
Organogenesis acquires NuTech Medical
Organogenesis said today that it acquired NuTech Medical for an undisclosed price. The combined company plans to feature a portfolio of wound care products and surgical biologics. Birmingham, Alabama-based NuTech Medical will keep it’s non-biologics product line as a separate company called NuTech Spine. Get the full story at our sister site, Drug Delivery Business News.
Organogenesis launches PuraPly antimicrobial clinical program
Organogenesis said today that it launched its PuraPly Antimicrobial clinical research program, which will evaluate patients treated with PuraPly AM for up to 12 weeks. The 1st studies have started enrolling patients, according to Organogenesis. The Canton, Mass.-based company’s PuraPly AM is a 510(k)-cleared device indicated for the management of acute and chronic wounds. The […]
